TY - JOUR

T1 - Long-term risk of second malignant neoplasm after a cancer in childhood

AU - De Vathaire, F.

AU - Schweisguth, O.

AU - Rodary, C.

AU - Francois, P.

AU - Sarrazin, D.

AU - Oberlin, O.

AU - Hill, C.

AU - Raquin, M. A.

AU - Dutreix, A.

AU - Flamant, R.

PY - 1989/1/1

Y1 - 1989/1/1

N2 - The risk of subsequent second malignant neoplasm was studied in a cohort of 634 patients, treated for a childhood cancer at the Gustave Roussy Institute between 1942 and 1969, and in complete remission five years after diagnosis. The most frequent types of first primary cancers (FPC) were Wilms’ tumours (28% of the children), neuroblastomas (16%), lymphomas (12%) and soft tissue sarcomas (11%). Median follow-up duration after FPC was 19 years. Thirty-two patients (obs = 32) developed a total of 35 second cancers. Bone, thyroid, connective tissues and skin were the most frequent types of second cancer, with six patients for each type. The average annual incidence of second cancer was 0.36%. The average annual incidence for the periods 5–9, 10–14, 15–19, 20–24 and 25+ years after FPC was respectively 0.16%, 0.34%, 0.36%, 0.71% and 1.18%. The cumulative incidence of second cancer for the periods 5–20, 5–25 and 5–30 years after FPC was, respectively, 4.3% (95% Cl: 2.8–6.6%), 7.8% (95% Cl: 5.1–11.8%) and 13.0% (95% Cl: 8.2–20.0%). The expected number of cancers in the cohort, computed from Danish cancer incidence data, was exp = 2.2. When compared to this expected number, the average annual excess incidence of second cancer, defined as obs–exp divided by the number of person years of observation, was 0.33%. This rose from 0.15% for the period 5–9 years after FPC to 1.09% for the period beginning 25 years after FPC. The standardised incidence ratio of second cancer (i.e. obs/exp) was 15 (95% Cl: 10–21), and was fairly constant in the period extending from 15 to 20 years after FPC diagnosis. Obs/exp was equal to 25 for the patients who had had chemotherapy and equal to 9 for those who had not. Cyclophosphamide seemed less carcinogenic than the other alkylating agents. Obs/exp was similar for the patients who had received radiotherapy and for those who had not. The risk of cancer increased with age in the reference population and increased faster in the cohort, because the standardised incidence ratio is constant over a long period.

AB - The risk of subsequent second malignant neoplasm was studied in a cohort of 634 patients, treated for a childhood cancer at the Gustave Roussy Institute between 1942 and 1969, and in complete remission five years after diagnosis. The most frequent types of first primary cancers (FPC) were Wilms’ tumours (28% of the children), neuroblastomas (16%), lymphomas (12%) and soft tissue sarcomas (11%). Median follow-up duration after FPC was 19 years. Thirty-two patients (obs = 32) developed a total of 35 second cancers. Bone, thyroid, connective tissues and skin were the most frequent types of second cancer, with six patients for each type. The average annual incidence of second cancer was 0.36%. The average annual incidence for the periods 5–9, 10–14, 15–19, 20–24 and 25+ years after FPC was respectively 0.16%, 0.34%, 0.36%, 0.71% and 1.18%. The cumulative incidence of second cancer for the periods 5–20, 5–25 and 5–30 years after FPC was, respectively, 4.3% (95% Cl: 2.8–6.6%), 7.8% (95% Cl: 5.1–11.8%) and 13.0% (95% Cl: 8.2–20.0%). The expected number of cancers in the cohort, computed from Danish cancer incidence data, was exp = 2.2. When compared to this expected number, the average annual excess incidence of second cancer, defined as obs–exp divided by the number of person years of observation, was 0.33%. This rose from 0.15% for the period 5–9 years after FPC to 1.09% for the period beginning 25 years after FPC. The standardised incidence ratio of second cancer (i.e. obs/exp) was 15 (95% Cl: 10–21), and was fairly constant in the period extending from 15 to 20 years after FPC diagnosis. Obs/exp was equal to 25 for the patients who had had chemotherapy and equal to 9 for those who had not. Cyclophosphamide seemed less carcinogenic than the other alkylating agents. Obs/exp was similar for the patients who had received radiotherapy and for those who had not. The risk of cancer increased with age in the reference population and increased faster in the cohort, because the standardised incidence ratio is constant over a long period.

UR - http://www.scopus.com/inward/record.url?scp=0024550471&partnerID=8YFLogxK

U2 - 10.1038/bjc.1989.92

DO - 10.1038/bjc.1989.92

M3 - Article

C2 - 2930714

AN - SCOPUS:0024550471

SN - 0007-0920

VL - 59

SP - 448

EP - 452

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 3

ER -